Immune globulin subcutaneous, human – klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.

MLA

Sleasman, John W., et al. “Immune Globulin Subcutaneous, Human – Klhw 20% for Primary Humoral Immunodeficiency: An Open-Label, Phase III Study.” Immunotherapy (1750743X), vol. 11, no. 16, Sept. 2019, pp. 1371–86. EBSCOhost, https://doi.org/10.2217/imt-2019-0159.

APA

Sleasman, J. W., Lumry, W. R., Hussain, I., Wedner, H. J., Harris, J. B., Courtney, K. L., Mondou, E., Lin, J., & Stein, M. R. (2019). Immune globulin subcutaneous, human – klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study. Immunotherapy (1750743X), 11(16), 1371–1386. https://doi.org/10.2217/imt-2019-0159

Chicago

Sleasman, John W, William R Lumry, Iftikhar Hussain, H James Wedner, James B Harris, Kecia L Courtney, Elsa Mondou, Jiang Lin, and Mark R Stein. 2019. “Immune Globulin Subcutaneous, Human – Klhw 20% for Primary Humoral Immunodeficiency: An Open-Label, Phase III Study.” Immunotherapy (1750743X) 11 (16): 1371–86. doi:10.2217/imt-2019-0159.